This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Transforming growth factor- β receptor 1 (TGFBRI; ALK5)	<i>In vitro</i> studies suggest that analogs of 4-pyridinoxy-2-anilopyridine could inhibit ALK5 to treat cancer. Cellular assays identified a pyridinoxy-2-anilopyridine scaffold that had low nanomolar activity against ALK5, a receptor implicated in multiple cancers. An SAR study of 15 analogs of the scaffold identified a lead compound with low nanomolar activity against ALK5 and high bioavailability in rats. Future studies could include testing the efficacy of the lead compound in animal models of cancer.	Patented by AstraZeneca plc; licensing status undisclosed	Goldberg, F. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Sept. 8, 2009; doi:10.1021/jm900807w Contact: Richard A. Ward, AstraZeneca plc, Macclesfield, U.K. e-mail: Richard.A.Ward@astrazeneca.com Contact: Frederick W. Goldberg, same affiliation as above e-mail: Frederick.Goldberg@astrazeneca.com
<i>SciBX</i> 2(37); doi:10.1038/scibx.2009.1400 Published online Sept. 24, 2009				